IP Verse

Treatment Of Prostate Cancer

Patent No. EP3518932 (titled "Treatment Of Prostate Cancer") was filed by Myovant Sciences on Sep 29, 2017. The application was issued on Nov 13, 2024.

Patent Summary

Methods for treating prostate cancer using a once-daily oral formulation of a GnRH antagonist, allowing for suspension of treatment to increase serum testosterone levels. The formulation rapidly inhibits sex hormone production without clinical flare, enabling rapid recovery from surgery, radiation therapy, or illness. Treatment can be suspended for planned or unplanned events, with testosterone levels returning to baseline after treatment resumes. The formulation provides more control for patients and physicians compared to depot formulations, enabling flexible treatment management.

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ABG LAWAug 7, 2025-
SANDOZAug 7, 2025ELKINGTON AND FIFE

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3518932

MYOVANT SCIENCES
Application Number
EP17823017A
Filing Date
Sep 29, 2017
Status
Granted And Under Opposition
Oct 11, 2024
Publication Date
Nov 13, 2024
External Links
Slate, Register , Google Patents